Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Macrolide antibiotic authorised for use in paediatrics. Commonly used in young infants. Oral administration in two or more daily doses.
At the date of the last update, we found no published data on its excretion in breast milk.
It has a higher molecular weight and shorter elimination half-life than other macrolides (azithromycin, clarithromycin) that are excreted in insignificant amounts in breast milk. It is much more lipophilic than erythromycin.
Until more published data on this drug in relation to breastfeeding is available, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.
Early exposure to macrolides (especially erythromycin) has been linked to the onset of hypertrophic pyloric stenosis, even through breast milk, so it may be prudent to avoid them during the first month of breastfeeding.